Among the biotech small-cap stocks, Vidac Pharma has recently made headlines. The British-Israeli company has recently published promising results of its studies with the promising compound VDA-1275 in several mouse and human cellular organoid models of solid tumours in a scientific article. The paper has been submitted for independent peer review. The associated study demonstrates that VDA-1275 exhibited statistically significant efficacy as a monotherapy and synergistic effects in combination with two standard cancer therapies and also elicited an immunological response.
News & Events